Circulating mitochondrial DNA is associated with anemia in newly diagnosed hematologic malignancies. Issue 1 (2nd January 2023)

• Record Type: Journal Article
• Authors: Yue, Liang; Li, Yu-Hang; Ma, Rui-Lin; Niu, Jing-Wen; Cui, Hong-Tu; Sun, Yao; Yun, Zhi-Min; Zhuo, Hai-Long; Wan, Lu-Ming; Li, Su-Bo; Zhang, Xue; Wu, Cheng-Jun; Hu, Liang-Ding; Tan, Ying-Xia
• Is Part Of: Leukemia & lymphoma. Volume 64:Issue 1(2023)
• Page Start: 178
• Page End: 187
• Publication Date: 2023-01-02
• Subjects: Mitochondrial DNA -- hematologic malignancies -- anemia -- RBC; Leukemia -- Periodicals; Lymphomas -- Periodicals; 616.99419
• DOI: 10.1080/10428194.2022.2133537
• Languages: English
• ISSNs: 1042-8194

Abstract

Abstract: Recent reports discovered that red blood cells (RBCs) could scavenge cell-free mitochondrial DNA (mtDNA), which drives the accelerated erythrophagocytosis and innate immune activation characterized by anemia and inflammatory cytokine production. However, the clinical value of the circulating mtDNA copy number alterations in hematologic malignancies is poorly understood. Our data showed that in comparison to healthy group, the patients group had significantly higher mtDNA and histone H4 levels. Moreover, we observed that RBC-bound mtDNA and histone H4 were negatively correlated with hemoglobin in patients. In addition, cytokines and chemokines levels in patients differed significantly from normal controls (21 higher, 7 lower). Our study suggested that both circulating mtDNA and histone H4 were associated with anemia in hematologic malignancies, which helps to further understand the potential mechanism of anemia development in patients with hematologic malignancies. This information may play a vital role in the specific therapeutic interventions for leukemia in the future.